Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Madhi, SA; Koen, AL; Izu, A; Fairlie, L; Cutland, CL; Baillie, V; Padayachee, SD; Dheda, K; Barnabas, SL; Bhorat, QE; Briner, C; Aley, PK; Bhikha, S; Hermanus, T; Horne, E; Jose, A; Kgagudi, P; Lambe, T; Masenya, M; Masilela, M; Mkhize, N; Moultrie, A; Mukendi, CK; Moyo-Gwete, T; Nana, AJ; Nzimande, A; Patel, F; Rhead, S; Taoushanis, C; Thombrayil, A; van Eck, S; Voysey, M; Villafana, TL; Vekemans, J; Gilbert, SC; Pollard, AJ; Moore, PL; Kwatra, G

Journal article

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Abstract:: Background
People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV and HIV-negative individuals in South Africa.
Methods
In this ongoing, double-blind, placebo-controlled, phase 1B/2A trial (COV005), people with HIV and HIV-negative participants a... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Madhi, S. A., Koen, A. L., Izu, A., Fairlie, L., Cutland, C. L., Baillie, V., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Aley, P. K., Bhikha, S., Hermanus, T., Horne, E., Jose, A., Kgagudi, P., Lambe, T., Masenya, M., … Kwatra, G. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. The Lancet. HIV, 8(9), e568–e580.

MLA Style

Madhi, S. A., et al. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without HIV in South Africa: an Interim Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 1B/2A Trial.” The Lancet. HIV, vol. 8, no. 9, Elsevier, 2021, pp. e568–e580.

Chicago Style

Madhi, SA, AL Koen, A Izu, L Fairlie, CL Cutland, V Baillie, SD Padayachee, et al. 2021. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without HIV in South Africa: an Interim Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 1B/2A Trial.” The Lancet. HIV 8 (9): e568–e580.
Tweet
Print